Skip to main content
OpenTrials

Clinical trial condition

Carcinoma

Explore clinical trials studying Carcinoma. Study availability and eligibility vary by location and protocol.

8,764 public trials 2,078 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma trial results

Active, Not Recruiting

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

NCT04868877

Conditions
Carcinoma, Carcinoma, Squamous Cell, Colonic Diseases, +24 more
Locations
  • University of California, Irvine Orange, California, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
  • START Mountain Region West Valley City, Utah, United States
  • Next Oncology Virginia Fairfax, Virginia, United States
View all 51 locations
View Trial Details
Active, Not Recruiting

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

NCT03252938

Conditions
Abdominal Neoplasms, Carcinoma, Carcinoma, Transitional Cell, +12 more
Locations
  • Helios Klinikum Bad Saarow Bad Saarow, Germany
  • Kliniken der Stadt Köln gGmbH, Studienzentrum der Lungenklinik, Krankenhaus Merheim Cologne, Germany
  • Universitätsklinikum Essen Essen, Germany
  • Agaplesion Markus Krankenhaus Frankfurter Diakonie Kliniken gGmbH Frankfurt, Germany
View Trial Details
Active, Not Recruiting

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334

Conditions
Carcinoma, Carcinoma, Transitional Cell, Locally Advanced Urothelial Carcinoma, +5 more
Locations
  • University of California San Francisco HDFCCC ( Site 4044) San Francisco, California, United States
  • University of Chicago Medical Center ( Site 4037) Chicago, Illinois, United States
  • Indiana University Melvin and Bren Simon Cancer Center ( Site 4011) Indianapolis, Indiana, United States
  • Dana-Farber Cancer Institute ( Site 4047) Boston, Massachusetts, United States
View all 25 locations
View Trial Details
Active, Not Recruiting

A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

NCT06041802

Conditions
Carcinoma, Carcinoma, Squamous Cell, Neoplasms, +5 more
Locations
  • Nagoya University Hospital ( Site 0003) Nagoya, Aichi-ken, Japan
  • Sapporo Medical University Hospital ( Site 0002) Sapporo, Hokkaido, Japan
  • Yokohama City University Hospital ( Site 0016) Yokohama, Kanagawa, Japan
  • Tohoku University Hospital ( Site 0019) Sendai, Miyagi, Japan
View all 18 locations
View Trial Details

Related conditions